| Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability AK Dutta, JL Fink, JP Grady, GJ Morgan, CG Mullighan, LB To, DR Hewett, ... Leukemia 33 (2), 457-468, 2019 | 119 | 2019 |
| Brief report: the differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation SK Martin, S Fitter, AK Dutta, MP Matthews, CR Walkley, MN Hall, ... Stem cells 33 (4), 1359-1365, 2015 | 89 | 2015 |
| Resilin-mimetics as a smart biomaterial platform for biomedical applications R Balu, NK Dutta, AK Dutta, NR Choudhury Nature Communications 12 (1), 149, 2021 | 74 | 2021 |
| Single-cell profiling of tumour evolution in multiple myeloma—opportunities for precision medicine AK Dutta, JB Alberge, R Sklavenitis-Pistofidis, ED Lightbody, G Getz, ... Nature Reviews Clinical Oncology 19 (4), 223-236, 2022 | 68 | 2022 |
| Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma AK Dutta, DR Hewett, JL Fink, JP Grady, ACW Zannettino British Journal of Haematology 178 (2), 196-208, 2017 | 28 | 2017 |
| Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma R Sklavenitis-Pistofidis, MP Aranha, RA Redd, J Baginska, ... Cancer Cell 40 (11), 1358-1373. e8, 2022 | 19 | 2022 |
| Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes M Bustoros, S Anand, R Sklavenitis-Pistofidis, R Redd, EM Boyle, ... Nature communications 13 (1), 3449, 2022 | 14 | 2022 |
| MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology AK Dutta, JB Alberge, ED Lightbody, CJ Boehner, A Dunford, ... Cancer discovery 13 (2), 348-363, 2023 | 8 | 2023 |
| Using genomics to better define high-risk MGUS/SMM patients AK Dutta, DR Hewett, JL Fink, ACW Zannettino Oncotarget 9 (93), 36549, 2018 | 4 | 2018 |
| Whole exome sequencing of paired MGUS/SMM to MM patients reveals novel subclonal tumour evolution models in disease progression of multiple myeloma AK Dutta, JP Grady, DR Hewett, LB To, L Fink, ACW Zannettino Blood 130, 391, 2017 | 2 | 2017 |
| Single-cell RNA sequencing of rare circulating tumor cells in precursor myeloma patients reveals molecular underpinnings of tumor cell circulation ED Lightbody, DT Firer, R Sklavenitis-Pistofidis, J Tsuji, MP Agius, ... Blood 140 (Supplement 1), 602-603, 2022 | 1 | 2022 |
| High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients ED Lightbody, H Keshishian, H El-Khoury, AK Dutta, H Barr, J Barbagallo, ... Blood 140 (Supplement 1), 4303-4304, 2022 | 1 | 2022 |
| Single-cell RNA-sequencing of 245 tumor samples from patients with MGUS and smoldering multiple myeloma reveals novel insights into malignant plasma cell biology J Tsuji, ED Lightbody, R Sklavenitis-Pistofidis, MP Agius, M Rahmat, ... Blood 140 (Supplement 1), 254-255, 2022 | 1 | 2022 |
| Protein, Biomimetic Protein, and Designer Peptide-directed Synthesis of Metal Nanoparticles, Metal Nanoclusters and Nanobioconjugates, and Their Potential Applications AK Dutta, NK Dutta | 1 | 2022 |
| Non-Invasive Liquid Biopsy to Quantify and Molecularly Characterize Circulating Multiple Myeloma Cells in the Assessment of Precursor Disease Pathology AK Dutta, ED Lightbody, Z Lin, JB Alberge, R Sklavenitis-Pistofidis, ... Blood 138, 78, 2021 | 1 | 2021 |
| Single-cell RNA-sequencing identifies immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma R Sklavenitis-Pistofidis, AK Dutta, S Ujwary, RA Redd, A Savell, L Fléchon, ... Blood 138, 330, 2021 | 1 | 2021 |
| MRDetect: An Ultrasensitive Solution to Monitor Low Tumor Burden in Liquid Biopsies ED Lightbody, AK Dutta, IM Ghobrial The Hematologist 17 (5), 2020 | 1 | 2020 |
| Genomic profiling of Mycosis Fungoides identifies patients at high risk of disease progression L Fléchon, I Arib, AK Dutta, L Hasan Bou Issa, R Sklavenitis-Pistofidis, ... Blood Advances, bloodadvances. 2023012125, 2024 | | 2024 |
| Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib … O Nadeem, M Aranha, R Redd, M Timonian, S Magidson, E Lightbody, ... medRxiv, 2024.04. 19.24306082, 2024 | | 2024 |
| Genome Sequencing to Discover Drivers of Clonal Expansion in Smoldering Multiple Myeloma JB Alberge, AK Dutta, ED Lightbody, A Poletti, S Wallin, A Dunford, ... Blood 142, 4143, 2023 | | 2023 |
